PATRYS LIMITED — Director's Dealing 2025

Aug 28, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Patrys Limited
ABN	97 123 055 363

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director James Campbell

Date of last notice 8 July 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest		Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.		Barrabool Biotechnology Pty Ltd <J and KCampbell Family A/C>Dr. Campbell is a beneficiary of the aboveentity
Date of change		28 August 2025
No. of securities held prior to change		Direct:17,383,125 Fully paid ordinary shares23,389,950 Unlisted options, exercisableat $0.059 (5.9 cents), expiring on 30September 2025Indirect:1,502,000 Fully paid ordinary shares
Class		Fully paid ordinary shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number acquired		Direct:16,296,678 fully paid ordinary sharesIndirect:1,408,125 fully paid ordinary shares
Number disposed		-
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation		$14,163.84 ($0.001 per share)
No. of securities held after change		Direct:33,679,803 Fully paid ordinary shares23,389,950 Unlisted options, exercisableat $0.059 (5.9 cents), expiring on 30September 2025Indirect:2,910,125 Fully paid ordinary shares
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy-back		Take-upofEntitlementsintheEntitlement Offer as announced on 23July 2025.

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interestrelated prior to changeNote: Details are only required for a contract in relation to whichthe interest has changed	N/A
Interest acquired	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contractsdetailed above traded during a+closed periodwhere prior written clearance was required?	No
If so, was prior written clearance provided toallow the trade to proceed during this period?	N/A
If prior written clearance was provided, on whatdate was this provided?	N/A

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3